MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Vanda Pharmaceuticals Net Debt 2011-2026 | VNDA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Vanda Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -78.6 M | -96.7 M | -127 M | -124 M | -40.2 M | -48 M | -30.5 M | -61 M | -33.6 M | -40.4 M | -50.8 M | -60.9 M | -64.8 M | -88.8 M | -87.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -30.5 M | -127 M | -68.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Xeris Pharmaceuticals
XERS
|
116 M | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
11.9 M | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
-26.7 M | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
-5.5 M | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-60.8 M | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-48.9 M | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
-48.6 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
612 M | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
-47.4 M | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-7.85 M | $ 1.38 | -0.72 % | $ 63.3 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-35.2 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
Teligent, Inc.
TLGT
|
131 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
-130 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
-189 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
59.5 B | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-19.9 M | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
-26.2 M | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.67 | -1.38 % | $ 2.61 B | USA |